-+ 0.00%
-+ 0.00%
-+ 0.00%

OKYO Pharma Secures US Patent Covering OK-101's Potential To Treat Symptoms Of Dry Eye Disease

Benzinga·08/27/2024 11:01:52
Listen to the news

OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease.